Company details

CROSSJECT

  • Print
  • Share Share
en fr

Crossject is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, severe migraine, allergic shock, overdose and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and has notably received financing from Bpifrance.